Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats

S M Manschot, G J Biessels, Norman E Cameron, M A Cotter, A Kamal, L J Kappelle, W H Gispen

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Vascular dysfunction is important in the pathogenesis of peripheral complications of diabetes. However, the effects of diabetes on cerebral blood flow and the role of vascular deficits in the pathogenesis of diabetic encephalopathy are still unknown. The present study examined whether experimental diabetes is associated with reduced cerebral blood flow and whether treatment with enalapril can improve cerebral perfusion and function (blood flow and functional cerebral deficits). Streptozotocin-diabetic rats were treated with the ACE inhibitor enalapril (24 mg/kg) from onset of diabetes. After 14 weeks of diabetes, 12 enalapril treated and 12 untreated diabetic rats, and 12 nondiabetic age-matched control rats were tested in a spatial version of the Morris water maze. After 16 weeks of diabetes, in the same groups, blood flow in the hippocampus and thalamus was measured by hydrogen clearance microelectrode polarography. In a separate study, hippocampal long-term potentiation was measured after 26 weeks of diabetes. Water maze performance and hippocampal long-term potentiation were impaired in diabetic rats. Furthermore, blood flow in diabetic rats was reduced by 30% (P<0.001) in the hippocampus and by 37% (P<0.005) in the thalamus compared to nondiabetic controls. Enalapril treatment significantly improved water maze performance (P<0.05), hippocampal long term potentiation (P<0.05) and hippocampal blood flow (P<0.05). Cerebral perfusion is reduced in diabetic rats compared to controls. Treatment aimed at the vasculature can improve cerebral blood flow, deficits in Morris maze performance and long term potentiation. These findings suggest that vasculopathy plays a role in the development of cerebral dysfunction in diabetic-rats. (C) 2002 Elsevier Science B.V. All rights reserved.

Original languageEnglish
Pages (from-to)274-282
Number of pages9
JournalBrain Research
Volume966
DOIs
Publication statusPublished - 2003

Keywords

  • diabetic rat
  • streptozotocin
  • cerebral dysfunction
  • cerebral blood flow
  • enalapril
  • angiotensin converting enzyme
  • Morris water maze
  • hippocampal plasticity
  • LONG-TERM POTENTIATION
  • HYDROGEN CLEARANCE
  • HYPERTENSIVE RATS
  • INSULIN-TREATMENT
  • NERVOUS-SYSTEM
  • SCIATIC-NERVE
  • MELLITUS
  • IMPAIRMENT
  • DEMENTIA
  • COMPLICATIONS

Cite this

Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. / Manschot, S M ; Biessels, G J ; Cameron, Norman E; Cotter, M A ; Kamal, A ; Kappelle, L J ; Gispen, W H .

In: Brain Research, Vol. 966, 2003, p. 274-282.

Research output: Contribution to journalArticle

Manschot, S M ; Biessels, G J ; Cameron, Norman E ; Cotter, M A ; Kamal, A ; Kappelle, L J ; Gispen, W H . / Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. In: Brain Research. 2003 ; Vol. 966. pp. 274-282.
@article{e928c9ef48004ac1b81376c0ccbf520b,
title = "Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats",
abstract = "Vascular dysfunction is important in the pathogenesis of peripheral complications of diabetes. However, the effects of diabetes on cerebral blood flow and the role of vascular deficits in the pathogenesis of diabetic encephalopathy are still unknown. The present study examined whether experimental diabetes is associated with reduced cerebral blood flow and whether treatment with enalapril can improve cerebral perfusion and function (blood flow and functional cerebral deficits). Streptozotocin-diabetic rats were treated with the ACE inhibitor enalapril (24 mg/kg) from onset of diabetes. After 14 weeks of diabetes, 12 enalapril treated and 12 untreated diabetic rats, and 12 nondiabetic age-matched control rats were tested in a spatial version of the Morris water maze. After 16 weeks of diabetes, in the same groups, blood flow in the hippocampus and thalamus was measured by hydrogen clearance microelectrode polarography. In a separate study, hippocampal long-term potentiation was measured after 26 weeks of diabetes. Water maze performance and hippocampal long-term potentiation were impaired in diabetic rats. Furthermore, blood flow in diabetic rats was reduced by 30{\%} (P<0.001) in the hippocampus and by 37{\%} (P<0.005) in the thalamus compared to nondiabetic controls. Enalapril treatment significantly improved water maze performance (P<0.05), hippocampal long term potentiation (P<0.05) and hippocampal blood flow (P<0.05). Cerebral perfusion is reduced in diabetic rats compared to controls. Treatment aimed at the vasculature can improve cerebral blood flow, deficits in Morris maze performance and long term potentiation. These findings suggest that vasculopathy plays a role in the development of cerebral dysfunction in diabetic-rats. (C) 2002 Elsevier Science B.V. All rights reserved.",
keywords = "diabetic rat, streptozotocin, cerebral dysfunction, cerebral blood flow, enalapril, angiotensin converting enzyme, Morris water maze, hippocampal plasticity, LONG-TERM POTENTIATION, HYDROGEN CLEARANCE, HYPERTENSIVE RATS, INSULIN-TREATMENT, NERVOUS-SYSTEM, SCIATIC-NERVE, MELLITUS, IMPAIRMENT, DEMENTIA, COMPLICATIONS",
author = "Manschot, {S M} and Biessels, {G J} and Cameron, {Norman E} and Cotter, {M A} and A Kamal and Kappelle, {L J} and Gispen, {W H}",
year = "2003",
doi = "10.1016/S0006-8993(02)04211-7",
language = "English",
volume = "966",
pages = "274--282",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats

AU - Manschot, S M

AU - Biessels, G J

AU - Cameron, Norman E

AU - Cotter, M A

AU - Kamal, A

AU - Kappelle, L J

AU - Gispen, W H

PY - 2003

Y1 - 2003

N2 - Vascular dysfunction is important in the pathogenesis of peripheral complications of diabetes. However, the effects of diabetes on cerebral blood flow and the role of vascular deficits in the pathogenesis of diabetic encephalopathy are still unknown. The present study examined whether experimental diabetes is associated with reduced cerebral blood flow and whether treatment with enalapril can improve cerebral perfusion and function (blood flow and functional cerebral deficits). Streptozotocin-diabetic rats were treated with the ACE inhibitor enalapril (24 mg/kg) from onset of diabetes. After 14 weeks of diabetes, 12 enalapril treated and 12 untreated diabetic rats, and 12 nondiabetic age-matched control rats were tested in a spatial version of the Morris water maze. After 16 weeks of diabetes, in the same groups, blood flow in the hippocampus and thalamus was measured by hydrogen clearance microelectrode polarography. In a separate study, hippocampal long-term potentiation was measured after 26 weeks of diabetes. Water maze performance and hippocampal long-term potentiation were impaired in diabetic rats. Furthermore, blood flow in diabetic rats was reduced by 30% (P<0.001) in the hippocampus and by 37% (P<0.005) in the thalamus compared to nondiabetic controls. Enalapril treatment significantly improved water maze performance (P<0.05), hippocampal long term potentiation (P<0.05) and hippocampal blood flow (P<0.05). Cerebral perfusion is reduced in diabetic rats compared to controls. Treatment aimed at the vasculature can improve cerebral blood flow, deficits in Morris maze performance and long term potentiation. These findings suggest that vasculopathy plays a role in the development of cerebral dysfunction in diabetic-rats. (C) 2002 Elsevier Science B.V. All rights reserved.

AB - Vascular dysfunction is important in the pathogenesis of peripheral complications of diabetes. However, the effects of diabetes on cerebral blood flow and the role of vascular deficits in the pathogenesis of diabetic encephalopathy are still unknown. The present study examined whether experimental diabetes is associated with reduced cerebral blood flow and whether treatment with enalapril can improve cerebral perfusion and function (blood flow and functional cerebral deficits). Streptozotocin-diabetic rats were treated with the ACE inhibitor enalapril (24 mg/kg) from onset of diabetes. After 14 weeks of diabetes, 12 enalapril treated and 12 untreated diabetic rats, and 12 nondiabetic age-matched control rats were tested in a spatial version of the Morris water maze. After 16 weeks of diabetes, in the same groups, blood flow in the hippocampus and thalamus was measured by hydrogen clearance microelectrode polarography. In a separate study, hippocampal long-term potentiation was measured after 26 weeks of diabetes. Water maze performance and hippocampal long-term potentiation were impaired in diabetic rats. Furthermore, blood flow in diabetic rats was reduced by 30% (P<0.001) in the hippocampus and by 37% (P<0.005) in the thalamus compared to nondiabetic controls. Enalapril treatment significantly improved water maze performance (P<0.05), hippocampal long term potentiation (P<0.05) and hippocampal blood flow (P<0.05). Cerebral perfusion is reduced in diabetic rats compared to controls. Treatment aimed at the vasculature can improve cerebral blood flow, deficits in Morris maze performance and long term potentiation. These findings suggest that vasculopathy plays a role in the development of cerebral dysfunction in diabetic-rats. (C) 2002 Elsevier Science B.V. All rights reserved.

KW - diabetic rat

KW - streptozotocin

KW - cerebral dysfunction

KW - cerebral blood flow

KW - enalapril

KW - angiotensin converting enzyme

KW - Morris water maze

KW - hippocampal plasticity

KW - LONG-TERM POTENTIATION

KW - HYDROGEN CLEARANCE

KW - HYPERTENSIVE RATS

KW - INSULIN-TREATMENT

KW - NERVOUS-SYSTEM

KW - SCIATIC-NERVE

KW - MELLITUS

KW - IMPAIRMENT

KW - DEMENTIA

KW - COMPLICATIONS

U2 - 10.1016/S0006-8993(02)04211-7

DO - 10.1016/S0006-8993(02)04211-7

M3 - Article

VL - 966

SP - 274

EP - 282

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -